alefacept

ApprovedTerminated

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Chronic Plaque Psoriasis

Conditions

Chronic Plaque Psoriasis

Trial Timeline

Feb 1, 2008 → Dec 1, 2008

NCT ID

NCT00953329

About alefacept

alefacept is a approved stage product being developed by Astellas Pharma for Chronic Plaque Psoriasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00953329. Target conditions include Chronic Plaque Psoriasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01267643	Phase 1	Terminated	May 1, 2011	Apr 16, 2013	Aplastic Anemia
NCT01226420	Phase 2	Terminated	Oct 1, 2010	Aug 1, 2012	Chronic Graft-versus-host Disease
NCT00808223	Phase 2	Completed	Apr 1, 2009	Feb 1, 2012	Psoriasis
NCT00815633	Approved	Terminated	Dec 1, 2008	Mar 1, 2010	Pityriasis Rubra Pilaris
NCT00953329	Approved	Terminated	Feb 1, 2008	Dec 1, 2008	Chronic Plaque Psoriasis
NCT00832585	Approved	Completed	Jan 1, 2008	Oct 1, 2009	Atopic Dermatitis
NCT00658606	Approved	Completed	Oct 1, 2007	Dec 1, 2009	Plaque Psoriasis
NCT00168753	Approved	Completed	Jul 1, 2004	Mar 1, 2005	Moderate to Severe Chronic Plaque Psoriasis
NCT00674063	Phase 3	Completed	Jul 1, 2003	Apr 1, 2004	Chronic Plaque Psoriasis
NCT00692172	Phase 3	Completed	Dec 1, 2001	Nov 1, 2004	Psoriasis

Competing Products

20 competing products in Chronic Plaque Psoriasis

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved